Clinical trials: Apatinib
Advanced Pancreatic Cancer
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
The aim of this study was to determine the efficacy and safety of apatinib combined with S-1 on advanced pancreatic cancer patients after failure of first-line chemotherapy.
- Trial name
- ASPC (NCT03662035)
- Testing
- Apatinib, S-1
- Volunteers
- 30 people
- Sponsor
- Changzhou No.2 People's Hospital
Esophageal Cancer
Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.
To assess the efficacy and safety of adebrelimab in combination with apatinib mesylate and chemoradiotherapy in immuno-experienced second-line esophageal squamous cell carcinoma (with symptomatic dysphagia or oligometastatic…
- Trial name
- NCT06464614
- Testing
- Adebrelimab, Apatinib, Investigator chosen chemotherapy (ICC)
- Where
- China
- Volunteers
- 54 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Gastric Cancer
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
The investigators conduct the real world study to explore the efficacy and safety of Apatinib in gastric cancer .
- Trial name
- NCT03478943
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Henan Cancer Hospital
HCC
A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC
This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage.
- Trial name
- NCT07589244
- Testing
- VRT106, VRT106 in combination with camrelizumab and apatinib, Investigator's Choice of Standard of Care
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
Adenocarcinoma of the Lung
Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma
This study is a single arm, open label, national multicenter study, to explore the efficacy and safety of the combination of Camrelizumab, apatinib and albumin paclitaxel in advanced untreated EGFR Wild Type and ALK-negative Lung…
- Trial name
- NCT04459078
- Testing
- Camrelizumab, Albumin Paclitacxel, Apatinib
- Where
- 3 sites in China
- Volunteers
- 63 people
- Sponsor
- Hunan Cancer Hospital
Stomach Neoplasms, Gastrointestinal Neoplasms
The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer.
- Conditions
- Stomach Neoplasms, Gastrointestinal Neoplasms, Stomach Diseases, Digestive System Neoplasms
- Trial name
- NCT03889626
- Testing
- Apatinib, Capecitabine
- Volunteers
- 242 people
- Sponsor
- Fudan University
Esophageal Cancer
Study of Apatinib in Metastatic Esophageal Cancer
The purpose of this study is to assess the efficacy and safety of apatinib in Metastatic Esophageal Cancer.
- Trial name
- NCT02683655
- Testing
- Apatinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Huai'an First People's Hospital
AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
This study is a single-arm study aimed at evaluating the efficacy and safety of Iparomlimab and Tuvonralimab Injection combined with apatinib and irinotecan hydrochloride in the treatment of advanced alpha-fetoprotein gastric…
- Conditions
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC, Immunotherapy
- Trial name
- NCT07289997
- Testing
- Iparomlimab and Tuvonralimab Injection (QL1706)
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Hebei Medical University Fourth Hospital
Hepatocellular Carcinoma
TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
This study was designed to evaluate the effectiveness and safety of TACE（transcatheter arterial chemoembolization） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT05550025
- Testing
- camrelizumab& apatinib
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastroesophageal Junction Adenocarcinoma
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.
- Trial name
- NCT03986385
- Testing
- Apatinib Capecitabine Oxaliplatin, Capecitabine Oxaliplatin
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Hebei Medical University
Glioblastoma
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells.
- Trial name
- NCT03567135
- Testing
- Apatinib, Temozolomide（TMZ）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuzhou General Hospital
Differentiated Thyroid Carcinoma
Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma
This is a non-randomized, phase II, open label study of Apatinib Mesylate in patients with with locally advanced or metastatic differentiated thyroid carcinoma (DTC).
- Trial name
- NCT03167385
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Neoplasms
A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate
- Trial name
- NCT03787251
- Testing
- Apatinib, The chemotherapeutic drug chosen by the investigator.
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Hepatocellular Carcinoma
Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer
Literature has shown that radiotherapy can promote tumor antigen presentation, mobilize and activate T cells by enhancing activation signals and blocking inhibitory signals.
- Trial name
- NCT04523662
- Testing
- Camrelizumab Apatinib Mesylas
- Volunteers
- 27 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Radioactive Iodine-refractory Differentiated Thyroid Cancer
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
This is a single arm, open-label, non-randomized and single-center phase II clinical study, to evaluate the safety, tolerance, and efficacy of Camrelizumab in combination with Apatinib in patients with Radioactive…
- Trial name
- NCT04560127
- Testing
- Camrelizumab combination with Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Cancer
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
The purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients with platinum resistant or refractory ovarian cancer when combined with etoposide.
- Trial name
- NCT02867956
- Testing
- Apatinib, Etoposide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Triple-negative Breast Cancer
Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC
This is a prospective, randomized, open-label clinical study. 128 patients with relapsed or metastatic triple-negative breast cancer (TNBC) who had not been systematically treated are going to be enrolled and randomly assigned to…
- Trial name
- NCT05192798
- Testing
- Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab
- Where
- China
- Volunteers
- 128 people
- Sponsor
- The First Affiliated Hospital of Bengbu Medical University
Adebrelimab, Adenocarcinoma of GE Junction
Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
This is a prospective, single-center, single-arm, open phase II clinical study. Forty-nine participants with pathologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer are scheduled to be…
- Conditions
- Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of Stomach
- Trial name
- NCT07353684
- Testing
- Adebrelimab, Apatinib, SOX Chemotherapy
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Friendship Hospital
Nasopharyngeal Carcinoma
Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC
This study aims to explore a new, more effective and tolerable treatment regimen for patients with advanced recurrent/metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05854849
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Sun Yat-sen University
Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization
DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above.
- Conditions
- Intrahepatic Cholangiocarcinoma, Transarterial Chemoembolization, Apatinib, PD-1 Antibody
- Trial name
- NCT04834674
- Testing
- DEB-TACE combined with apatinib and PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute